In brief, this study demonstrated that the dsDPr of CEA+ sEVs can effectively distinguish sEVs derived from tumor patients and healthy individuals, which can be employed as a simple and cost-effective non-invasive screening technology to assist tumor diagnosis. The gene discussed is CEACAM5; the disease is neoplasm.